hackint0sh/New-Dataset huggingface dataset:
Our main objective is to explore how the presence of stressors and prenatal sars-cov-2 infection generates an abnormal inflammatory activity in the newborn, which is associated with neurodevelopmental disorders and which confers a greater risk of developing neuropsychiatric disorders. The biological information of the umbilical cord (fetus blood) and peripheral blood of the mother obtained after childbirth was provided by the cohort of women during the Covid19 pandemic monitored during their pregnancy, delivery, childbirth and postpartum. These samples and the clinical characterisation of the cohort of mothers and newborns, of which we will be able to do an exhaustive longitudinal follow-up, are tremendously valuable at this time. There is a need to establish new research strategies to understand the pathophysiology of neuropsychiatric diseases, and to discover new molecular and cellular mechanisms involved in the development of the CNS. conditions: Covid19 and Pregnancy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Severity of infection, time of infection. name: Mental health assessment name: biological measure: explore how the presence of stressors and prenatal sars-cov-2 infection generates an abnormal inflammatory activity in the newborn sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Universitario Virgen del Rocío city: Sevilla zip: 41013 country: Spain lat: 37.38283 lon: -5.97317 hasResults: False
nctId: NCT06362473 id: LIPIGEN-001 briefTitle: Lipid Transport Disorder Italian Genetic Record (LIPIGEN) acronym: LIPIGEN overallStatus: RECRUITING date: 2015-08-04 date: 2026-09-30 date: 2026-09-30 date: 2024-04-12 date: 2024-04-12 name: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) class: OTHER briefSummary: LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS).
The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients\' lives through more precise diagnosis and personalised treatments. conditions: Familial Hypercholesterolemia conditions: Genetic Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 10000 type: ESTIMATED name: Lipid-lowering treatments measure: Lipid profile of patients with genetic dyslipidemia measure: Genetic profile of patients with genetic dyslipidemia sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Multimedica status: RECRUITING city: Sesto san Giovanni state: Milano zip: 20099 country: Italy name: Fabio Pellegatta, MD role: CONTACT phone: 00390224209593 email: lipigen@sisa.it name: Fabio Pellegatta, MD role: PRINCIPAL_INVESTIGATOR lat: 45.53329 lon: 9.22585 hasResults: False
nctId: NCT06362460 id: RAY1216-23-03 briefTitle: Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China overallStatus: COMPLETED date: 2023-09-18 date: 2023-11-01 date: 2023-11-15 date: 2024-04-12 date: 2024-04-16 name: Guangdong Raynovent Biotech Co., Ltd class: INDUSTRY briefSummary: This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]RAY1216 in healthy Chinese male participants, revealing the overall pharmacokinetic characteristics of RAY1216. conditions: Pharmacokinetics studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 6 type: ACTUAL name: [14C] RAY1216 measure: Total radioactivity in plasma PK measure: Total radioactivity in plasma PK measure: Total radioactivity in plasma PK measure: Total radioactivity in plasma PK measure: Mass balance recovery of total radioactivity in all (urine, faeces) amount excreted (Ae) expressed as a percentage of the administered dose (%Ae) measure: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: The First Affiliated Hospital of Bengbu Medical College city: Bengbu country: China lat: 32.94083 lon: 117.36083 hasResults: False
nctId: NCT06362447 id: RC31/22/0320 briefTitle: Efficacy of Injectable Gentamicin in Hereditary Ichthyosis acronym: GENTIC overallStatus: NOT_YET_RECRUITING date: 2024-04-23 date: 2026-04-01 date: 2027-04-01 date: 2024-04-12 date: 2024-04-12 name: University Hospital, Toulouse class: OTHER briefSummary: This study will evaluate the efficacy and safety of intravenous gentamicin in congenital ichthyosis due to a non-sens mutation. The primary objective is the severity of scales and erythema at the third month, compared to baseline. Secondary objectives will include: the importance of itching, trans epidermal water loss, cutaneous expression of the targeted protein, the security of the drug and patients' satisfaction. conditions: Ichthyosis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 26 type: ESTIMATED name: Gentamicin Injectable Solution measure: Gentamicin efficacity measure: Gentamicin efficacity measure: Gentamicin efficacity on quality of life sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Saint-Louis APHP city: Paris zip: 75010 country: France name: BOURRAT Emmanuelle, MD role: CONTACT phone: 01 42 49 90 90 phoneExt: 33 email: emmanuelle.bourrat@aphp.fr lat: 48.85341 lon: 2.3488 facility: CHU de Toulouse city: Toulouse zip: 31059 country: France name: SEVERINO-FREIRE Maella, MD role: CONTACT phone: 05 67 77 81 41 phoneExt: 33 email: severino-freire.m@chu-toulouse.fr name: TEXIER Hélène role: CONTACT phone: 05 67 77 81 80 phoneExt: 33 email: texier.h@chu-toulouse.fr name: MAZEREEUW-HAUTIER Juliette, MD, PhD role: SUB_INVESTIGATOR lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06362434 id: UHN-HHREHAB-24-xxxx briefTitle: Visual Telerehabilitation in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour acronym: HHREHAB overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2027-06-01 date: 2027-06-01 date: 2024-04-12 date: 2024-04-12 name: University Health Network, Toronto class: OTHER name: Alberta Children's Hospital name: St. Justine's Hospital name: The Hospital for Sick Children name: British Columbia Children's Hospital briefSummary: Brain malignancies are the most common cause of death from cancer in the pediatric population and a major source of morbidity amongst survivors. Many children with a brain tumour often suffer from visual field defects (hemianopia) dramatically impacting their daily life with poorer social interaction, difficulties learning, playing sports and engaging with peers. Practically, they bump into people and objects and have problems in finding their way in unfamiliar places and in detecting incoming objects in their blind field. There is growing recognition of the diverse and deep impact of hemianopia on physical and mental health, quality of life, and social outcomes of the affected individuals and their family. However, despite the frequent impact of brain tumours on the visual function and functional vision, ophthalmologic evaluations are not standard of care for all brain tumour patients and there are no standardized protocols of vision loss management in the pediatric population with hemianopia. There is an unmet need of restoring perception in the blind field in individuals with hemianopia consecutive to pediatric brain tumor.
This intervention provides more equitable access to individuals, with the ability to receive rehabilitation therapy at home without supervision by a healthcare professional, meaning that Canadians living outside urban centres could take advantage of specialized therapies with remote supervision. This is the first study that could lead to a major change in the management of these patients. It could open the door for visual rehabilitation strategies to other population of visually impaired children, significantly impacting public health strategies. conditions: Hemianopsia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Audiovisual stimulation measure: Binocular Visual Field measure: Patient-related Outcome Measures - National Eye Institute - Visual Function Questionnaire - 25 measure: Patient-related Outcome Measures - World Health Organization - Quality of Life questionnaire - BREF measure: Reading Speed measure: Fixation Stability measure: Contrast Sensitivity measure: Brain Activity - Visually-evoked potentials measure: Retinal Integrity measure: Brain imaging - Tractography measure: Brain imaging - Retinotopy measure: Head tracking measure: Eye tracking sex: ALL minimumAge: 10 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Alberta Children's Hospital city: Calgary state: Alberta zip: T3B 6A8 country: Canada name: Lucie Lafay-Cousin, MD role: CONTACT phone: 403-955-7272 email: llafayco@ucalgary.ca name: Lucie Lafay-Cousin, MD role: PRINCIPAL_INVESTIGATOR lat: 51.05011 lon: -114.08529 facility: British Columbia Children's Hospital city: Vancouver state: British Columbia zip: V6H 3N1 country: Canada name: Sylvia Cheng, MD role: CONTACT phone: 604-875-2406 email: sylvia.cheng@cw.bc.ca name: Sylvia Cheng, MD role: PRINCIPAL_INVESTIGATOR lat: 49.24966 lon: -123.11934 facility: The Hospital for Sick Children city: Toronto state: Ontario zip: M5G 1E8 country: Canada name: Eric Bouffet, MD role: CONTACT phone: 416-813-7500 email: eric.bouffet@sickkids.ca name: Eric Bouffet, MD role: PRINCIPAL_INVESTIGATOR name: Uri Tabori, MD role: SUB_INVESTIGATOR name: Inci Yaman Bajin, MD role: SUB_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: Centre Hospitalier Universitaire Sainte-Justine city: Montreal state: Quebec zip: H3T 1C5 country: Canada name: Sebastien Perreault, MD role: CONTACT phone: 514-345-2372 email: s.perreault@umontreal.ca name: Sebastien Perreault, MD role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 facility: CHU de Québec city: Québec state: Quebec zip: G1J 1Z4 country: Canada name: Valerie Larouche, MD role: CONTACT phone: 418-654-2282 email: valerie.larouche@fmed.ulaval.ca name: Valerie Larouche, MD role: PRINCIPAL_INVESTIGATOR lat: 46.81228 lon: -71.21454 hasResults: False
nctId: NCT06362421 id: ONC-HN-2402 briefTitle: Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-07 date: 2024-04-12 date: 2024-04-12 name: Wake Forest University Health Sciences class: OTHER name: InnoTech Precision Medicine briefSummary: The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer. In this study, the methods required to detect human papillomavirus will be developed and tested in samples collected from patients with oropharyngeal squamous cell carcinoma and compared to samples collected from participants without cancer. conditions: Oropharyngeal Squamous Cell Carcinoma conditions: Human Papillomavirus Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Pre-Radiation Dental Evaluation/Sample Collection name: Pre-Study Visit name: Oral Medicine Consultation Visit/Sample Collection measure: Number of Participants with Sensitivity for Detection of HPV 16, 18 and gene ACTB measure: Number of Participants with Specificity Detection of HPV 16, 18 and gene ACTB measure: Overall Accuracy - All Participants sex: ALL minimumAge: 39 Years maximumAge: 59 Years stdAges: ADULT facility: Hayworth Cancer Center city: High Point state: North Carolina zip: 27262 country: United States name: Study Coordinator role: CONTACT phone: 336-713-1790 email: cbynum@wakehealth.edu lat: 35.95569 lon: -80.00532 facility: Atrium Health Wake Forest Baptist Comprehensive Cancer Center city: Winston-Salem state: North Carolina zip: 27157 country: United States name: Study Coordinator role: CONTACT phone: 336-713-1790 email: cbynum@wakehealth.edu name: Muhammad A Shazib, DMD role: PRINCIPAL_INVESTIGATOR lat: 36.09986 lon: -80.24422 hasResults: False
nctId: NCT06362408 id: PLAGH-DEX-PSM/IPTW-001 briefTitle: Effect of Dexmedetomidine on Postoperative Mental Disorders and Long-term Survival in Elderly Patients overallStatus: COMPLETED date: 2022-06-01 date: 2023-05-25 date: 2023-06-01 date: 2024-04-12 date: 2024-04-12 name: Chinese PLA General Hospital class: OTHER name: Beijing Tiantan Hospital name: First Affiliated Hospital of Guangxi Medical University name: The Affiliated Hospital Of Guizhou Medical University name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School name: Wuhan Union Hospital, China name: Fudan University briefSummary: China's aging population is causing an increase in the number of senior persons undergoing surgery. More and more clinicians are paying attention to the postoperative survival and mental health of elderly surgical patients.
Further exploration of evidence for evidence-based medicine is needed. Based on the above research background, this hypothesis is proposed: in elderly patients undergoing noncardiac surgery, intraoperative DEX is associated with a reduction in short-term postoperative mental disorders and a reduction in long-term postoperative mortality. conditions: Cohort Studies studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 6000 type: ACTUAL name: Dexmedetomidine measure: Postoperative mortality rate measure: The incidence of postoperative delirium measure: The incidence of postoperative anxiety measure: The incidence of postoperative depression measure: Postoperative sleep disorders measure: Surgical related complications measure: Postoperative quality of life evaluation sex: ALL minimumAge: 65 Years maximumAge: 110 Years stdAges: OLDER_ADULT facility: Chinese PLA General Hospital city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06362395 id: 24-5022 briefTitle: Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction acronym: ULTRAS overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2030-06 date: 2030-06 date: 2024-04-12 date: 2024-04-12 name: University Health Network, Toronto class: OTHER briefSummary: This international multi-centre phase 3 randomized control trial investigates whether giving a very high dose of radiation in a single treatment session (ultra-high dose: experimental) using advanced technology called MR-Linac is more effective than a high dose (control) for treating liver tumors that have spread from other parts of the body (liver metastases). This study also aims to identify predictors of treatment response and side effects by analyzing various factors such as imaging markers and genetic profiles.
By comparing ultra-high dose SBRT with standard high dose, the study aims to determine if the former can provide better tumor control with fewer side effects. If successful, this approach could offer a significant advancement in the treatment of liver metastases, potentially improving outcomes and quality of life for patients. conditions: Liver Metastases studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 114 type: ESTIMATED name: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT) measure: Local control (LC) of treated target lesion compared to high dose MR-guided stereotactic single-fraction radiation. measure: Overall survival (OS) measure: Progression free survival (PFS) measure: Intra-hepatic progression measure: Widespread progression. measure: Physician-assessed toxicities: National Cancer Institute (NCI) Common Terminology Criteria of Adverse Events (CTCAE) V.5. measure: Patients-reported toxicity: Patient Reported Outcomes - Common Terminology Criteria of Adverse Events (PRO CTCAE) V.1. measure: Quality of life (QOL): European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, Core 15 for Palliative Care (EORTC QLQ-C15-PAL) measure: Quality of life (QOL): European Organization for Research and Treatment of Cancer Quality of Life Questionnaires, liver metastases (EORTC QOQ-LM21). measure: Changes in the levels of circulating biomarkers (cell-free tumor DNA) in response to SBRT. measure: Changes in the levels of circulating biomarkers (cytokines) in response to SBRT. measure: Changes in the levels of circulating biomarkers (metabolites) in response to SBRT. measure: Changes in the levels of circulating biomarkers (immune cell populations) in response to SBRT. measure: Identification of MR imaging biomarkers in response to SBRT. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362382 id: 2024-zxm-01 briefTitle: Mobile Internet-based Remote Home Rehabilitation Improves Prognostic Function and Life Quality in Pulmonary Hypertension overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2026-04-22 date: 2026-05-01 date: 2024-04-12 date: 2024-04-12 name: China-Japan Friendship Hospital class: OTHER briefSummary: The goal of this clinical trial is to learn the effectiveness of remote home-based exercise rehabilitation using mobile Internet technology for patients with pulmonary hypertension，especically providing early and mid-term results of its effectiveness. The main questions it aims to answer are:
During their stay in the hospital, the patients of tele-rehabilitation training group were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training. The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved. After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily training sessions and intensive supervision and management by the online community at least once a week.
Visit the clinic at the 3rd month of the study. Extended follow-up up to 6 months may be considered if patients are cooperative and could complete the training program in the first 3 months. conditions: Pulmonary Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: tele-rehabilitation training name: health propaganda and education measure: changes in 6MWD after 3 months measure: changes in muscle mass after 3 months measure: peak VO2 measure: VO2peak% measure: VE/VCO2 slope measure: PET CO2 measure: Changes in muscle mass evaluated by CT measure: Changes in grip strength measure: the time for 5 sit-to-stand test measure: Quality of life measured by SF-36 after 3 months measure: Quality of life measured by SF-36 after 6 months measure: Quality of life measured by emPHasis-10 after 3 months measure: Quality of life measured by emPHasis-10 after 6 months measure: Changes in WHO Cardiac Function Classification measure: Change in NT-proBNP measure: Change in TAPSE by cardiac doppler ultrasound measure: Changes in hemodynamic indice after 6 months measure: Changes in sleep quality score after 3 months measure: Changes in sleep quality score after 6 months measure: Changes in psychosocial score after 3 months measure: Changes in psychosocial score after 6 months measure: All-cause mortality in 3 months measure: All-cause mortality in 6 months measure: The occurrence rate of primary events in pulmonary hypertension in 3 months measure: The occurrence rate of primary events in pulmonary hypertension in 6 months sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Fuwai Hospital city: Beijing state: Beijing zip: 100037 country: China name: Xiaoming Zhou, MD role: CONTACT phone: +86 88396992 email: zhouxmcmu@163.com name: Xiaoming Zhou, MD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06362369 id: 7HP-111 briefTitle: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-12-31 date: 2028-12-31 date: 2024-04-12 date: 2024-04-12 name: 7 Hills Pharma, LLC class: INDUSTRY briefSummary: This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b conditions: Advanced Cancer conditions: Advanced Solid Tumor conditions: Melanoma conditions: Metastasis conditions: Pleural Mesothelioma conditions: Renal Cell Carcinoma conditions: MSI-High conditions: Mismatch Repair Deficiency conditions: Colorectal Cancer conditions: Hepatocellular Carcinoma conditions: Hepatocellular Cancer conditions: Renal Cell Cancer conditions: Kidney Cancer conditions: Skin Cancer conditions: Non Small Cell Lung Cancer conditions: NSCLC conditions: Anaplastic Lymphoma Kinase Genomic Tumor Aberrations conditions: ALK Genomic Tumor Aberrations studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE maskingDescription: Phase 1b - Open Label count: 126 type: ESTIMATED name: Alintegimod name: Ipilimumab name: Nivolumab measure: Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 measure: Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 measure: Define RPTDs for Alintegimod measure: Characterize Pharmacokinetics of Alintegimod monotherapy by measuring Maximum Plasma Concentration (Cmax) measure: Characterize Pharmacokinetics of Alintegimod monotherapy by measuring Area Under the Curve (AUC) measure: Characterize Pharmacokinetics of Alintegimod plus ipilimumab by measuring Maximum Plasma Concentration (Cmax) measure: Characterize Pharmacokinetics of Alintegimod plus ipilimumab by measuring Area Under the Curve (AUC) measure: Determine Progression Free Survival (PFS) response in patients treated with Alintegimod plus ipilimumab followed by nivolumab using RECIST v1.1 tumor assessment criteria. measure: Determine Overall Response Rate (ORR) in patients treated with Alintegimod plus ipilimumab followed by nivolumab using RECIST v1.1 response assessment criteria. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Florida Cancer Specialists city: Lake Mary state: Florida zip: 32746 country: United States name: Study Coordinator role: CONTACT phone: 407-804-6133 name: Alexander Philipovskiy, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 28.75888 lon: -81.31784 facility: Dartmouth Hitchcock city: Lebanon state: New Hampshire zip: 03756 country: United States name: Study Coordinator role: CONTACT phone: 603-650-6345 name: Konstantin H Dragnev, MD role: PRINCIPAL_INVESTIGATOR lat: 43.64229 lon: -72.25176 facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Study Coordinator role: CONTACT phone: 713-792-4259 name: Apostolia-Maria Tsimberidou, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False